Eptinezumab

Calcitonin Gene-related Peptide Antagonist — NERVOUS SYSTEM

Key facts

Eptinezumab is a drug in the Calcitonin Gene-related Peptide Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2020. Its mechanism of action is classified as Calcitonin Gene-related Peptide Antagonists. DrugCentral lists 2 molecular targets, including CALCA and CALCB. Recorded indications include Migraine and Prevention of migraine attacks.

• Drug class: Calcitonin Gene-related Peptide Antagonist.
• Mechanism of action: Calcitonin Gene-related Peptide Antagonists.
• Molecular targets: CALCA and CALCB (2 listed in DrugCentral).
• Indications: Migraine and Prevention of migraine attacks.
• ATC code: N02CD05 (Calcitonin gene-related peptide (CGRP) antagonists).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Migraine
• Prevention of migraine attacks

Mechanism & targets

• Mechanism of action (MoA): Calcitonin Gene-related Peptide Antagonists
• Established pharmacologic class: Calcitonin Gene-related Peptide Antagonist

Molecular targets (2)

Target	Gene	Action	Activity
Calcitonin gene-related peptide 1	CALCA	other	Kd 10.82
Calcitonin gene-related peptide 2	CALCB	other	Kd 10.24

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2022-01-24	EMA	—	H. LUNDBECK A/S
2020-02-21	FDA	—	Lundbeck Seattle BioPharmaceuticals, Inc.

ATC classification

ATC code	Therapeutic hierarchy
N02CD05	NERVOUS SYSTEM › ANALGESICS › ANTIMIGRAINE PREPARATIONS › Calcitonin gene-related peptide (CGRP) antagonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Throat irritation	544.2
Therapeutic response shortened	362.0
Drug effect less than expected	335.0
Drug ineffective	328.2
Headache	183.3
Chest discomfort	179.4
Pruritus	173.2
Nasal congestion	170.5
Sneezing	161.8
Nausea	124.5
Flushing	104.0
Infusion site extravasation	81.5

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Eptinezumab used for?

DrugCentral lists the following indications for Eptinezumab: Migraine and Prevention of migraine attacks.

How does Eptinezumab work?

Eptinezumab is classified as Calcitonin Gene-related Peptide Antagonists; its molecular targets in DrugCentral include CALCA and CALCB.

When was Eptinezumab first approved?

Eptinezumab was first approved by the FDA in 2020.

What drug class does Eptinezumab belong to?

Eptinezumab is in the Calcitonin Gene-related Peptide Antagonist class.

Sources

• DrugCentral drug card 5386 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3833320 — compound record and bioactivity
• DrugBank DB14040 — drug record
• FDA UNII 8202AY8I7H — substance identity
• DailyMed: FDA labels for Eptinezumab — current prescribing information (label search)
• UniProt P06881 (CALCA) — target protein
• UniProt P10092 (CALCB) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.